UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

See

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*McDermott Michael

(Last)

(First)

(Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK

NY

10001-2192

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol

PFIZER INC

[ PFE ]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director

10% Owner

Officer (give title below)

Other (specify below)

Executive Vice President

3. Date of Earliest Transaction

(Month/Day/Year)

02/23/2024

4. If Amendment, Date of Original Filed

(Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr.

3)

2. Transaction Date

(Month/Day/Year)

2A. Deemed Execution Date, if any

(Month/Day/Year)

3. Transaction Code (Instr.

8)

4. Securities Acquired (A) or Disposed Of (D) (Instr.

3, 4 and 5)

5.

Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.

3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr.

4)

7. Nature of Indirect Beneficial Ownership (Instr.

4)

Code

Amount

(A) or (D)

Price

Common Stock

02/23/2024

12,412(1)

$27.34

95,408

Common Stock

02/23/2024

859(2)

$27.76

94,549

Common Stock

02/23/2024

10,031(3)

$27.37(4)

84,518

Common Stock

02/25/2024

2,992(5)

$27.76(6)

81,526

Common Stock

02/26/2024

6,063(5)

$27.18

75,463

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr.

3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date

(Month/Day/Year)

3A. Deemed Execution Date, if any

(Month/Day/Year)

4. Transaction Code (Instr.

8)

5.

Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.

3, 4 and 5)

6. Date Exercisable and Expiration Date

(Month/Day/Year)

7. Title and Amount of Securities Underlying Derivative Security (Instr.

3 and 4)

8. Price of Derivative Security (Instr.

5)

9.

Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.

4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr.

4)

11. Nature of Indirect Beneficial Ownership (Instr.

4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Appreciation Rights

$27.34

02/23/2024

12,412

02/23/2024(7)

02/23/2024(7)

Common Stock

12,412

$0.0000

0.0000

Explanation of Responses:

1. The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

2. The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

3. The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

4. Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

5. The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

6. Price is the closing price of Pfizer common stock on February 23, 2024.

7. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

Susan E. Grant, by power of atty., for Michael McDermott

02/27/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person,

see

Instruction

(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations

See

18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,

see

Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.